Core for Cell Technology, School of Medicine, Pontifícia Universidade Catolica do Parana, Curitiba, Brazil.
Curr Stem Cell Res Ther. 2021;16(5):495-506. doi: 10.2174/1574888X16666210215160402.
Mesenchymal Stromal Cells (MSC) have the potential for self-renewal and differentiation in different tissues, characteristics that encourage their use in regenerative medicine. Dental tissue MSCs are easy to collect, have the same embryonic origin as neurons and have neuronal markers that allow their use in treating neurodegenerative diseases. Human Exfoliated Deciduous teeth (SHED)-derived stromal cells are considered immature and present positive expression of pluripotency and neuronal markers. Studies have shown that after the induction of neuronal differentiation in vitro, SHED increased the expression of neuronal markers, such as βIIItubulin, nestin, GFAP, NeuN, and NFM, demonstrating the potential use of these cells in preclinical studies. The results of this review reflect the consensus that in diseases such as spinal cord injury, cerebral ischaemia, and Alzheimer's and Parkinson's disease, SHED could function in the suppression of the inflammatory response, neuroprotection, and neuronal replacement.
For these cells to be used in large-scale clinical trials, standardization of the isolation techniques and theneuronal induction medium are necessary. The potential of SHED to induce neuronal differentiation is evident, demonstrating that this resource is promising and shows great potential for use in future preclinical and clinical trials of neurodegenerative diseases.
间充质基质细胞(MSC)具有在不同组织中自我更新和分化的潜力,这些特性鼓励它们在再生医学中应用。牙髓间充质基质细胞易于采集,与神经元具有相同的胚胎起源,并具有神经元标志物,允许其用于治疗神经退行性疾病。人脱落乳牙(SHED)来源的基质细胞被认为不成熟,并且具有多能性和神经元标志物的阳性表达。研究表明,在体外诱导神经元分化后,SHED 增加了神经元标志物的表达,如β III 微管蛋白、巢蛋白、GFAP、NeuN 和 NFM,表明这些细胞在临床前研究中的潜在用途。本综述的结果反映了这样一种共识,即在脊髓损伤、脑缺血和阿尔茨海默病和帕金森病等疾病中,SHED 可以抑制炎症反应、神经保护和神经元替代。
为了将这些细胞应用于大规模临床试验,有必要对分离技术和神经元诱导培养基进行标准化。SHED 诱导神经元分化的潜力是明显的,这表明这种资源很有前途,并显示出在未来神经退行性疾病的临床前和临床试验中具有很大的应用潜力。